close
References
  1. American Diabetes Association. Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S1-S212.
  2. Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972-1980.
  3. Aronson R, Umpierrez G, Stager W, Kovatchev B. Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia. Diabetes Obes Metab. 2019;21(3):726-731.
  4. Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of iDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009-1016.
  5. Blumer I, Pettus JH, Cavaiola TS. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgrad Med. 2018;130(4):375-380.
  6. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821.
  7. Browne JL, Ventura A, Mosely K, Speight J. 'I call it the blame and shame disease': a qualitative study about perceptions of social stigma surrounding type 2 diabetes. BMJ Open. 2013;3(11):e003384.
  8. Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (iDegLira). Diabetes Care. 2014;37(11):2926-2933.
  9. Buttigieg N, Ersser S, Cowdell F. The influence of social stigma on diabetes self-management amongst Maltese individuals with diabetes: Norma Buttigieg. Eur J Public Health. 2017;27(suppl 3):30.
  10. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20(3):497-507.
  11. ClinicalTrials.gov NCT01336023. Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes (DUAL™ I). Updated February 19, 2018. Accessed April 4, 2021.
  12. ClinicalTrials.gov NCT01392573. A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes (DUAL™ II). Updated January 3, 2019. Accessed April 4, 2021.
  13. ClinicalTrials.gov NCT01618162. The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy (DUAL™IV). Updated October 27, 2017. Accessed April 4, 2021.
  14. ClinicalTrials.gov NCT01676116. The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III). Updated January 3, 2019. Accessed April 4, 2021.
  15. ClinicalTrials.gov NCT01952145. A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V). Updated January 3, 2019. Accessed April 4, 2021.
  16. ClinicalTrials.gov NCT02058147. Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (LixiLan-O). Updated May 9, 2017. Accessed April 4, 2021.
  17. ClinicalTrials.gov NCT02058160. Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-L). Updated May 9, 2017. Accessed April 4, 2021.
  18. ClinicalTrials.gov NCT02298192. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms (DUAL™ VI). Updated May 23, 2017. Accessed April 4, 2021.
  19. ClinicalTrials.gov NCT02420262. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus. Updated March 29, 2018. Accessed April 4, 2021.
  20. David J, Fonseca V. When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered? J Diabetes Complications. 2019;33(12):107473.
  21. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
  22. Dickinson JK, Guzman SJ, Maryniuk MD, et al. The use of language in diabetes care and education. Diabetes Care. 2017;40(12):1790-1799.
  23. Dmowska A, Brown A. How Do We Reduce Diabetes Stigma and Guilt? Accessed Accessed April 4, 2021. https://diatribe.org/how-do-we-reduce-diabetes-stigma-and-guilt
  24. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (iDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885-893.
  25. Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of iDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017;19(6):858-865.
  26. Hartmann-Boyce J, Morris E, Goyder C, et al. Diabetes and COVID-19: risks, management, and learnings from other national disasters. Diabetes Care. 2020;43(8):1695-1703.
  27. Holmes-Truscott E, Browne JL, Ventura AD, Pouwer F, Speight J. Diabetes stigma is associated with negative treatment appraisals among adults with insulin-treated Type 2 diabetes: results from the second Diabetes MILES - Australia (MILES-2) survey. Diabet Med. 2018;35(5):658-662.
  28. King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsboll T. A fixed ratio combination of insulin degludec and liraglutide (iDegLira) reduces glycemic fluctuation and brings more patients with type 2 diabetes within blood glucose target ranges. Diabetes Technol Ther. 2017;19(4):255-264.
  29. Lingvay I, Perez Manghi F, Garcia-Hernandez P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315(9):898-907.
  30. Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of iDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 2017;8(1):101-114.
  31. Nuffer W, Guesnier A, Trujillo JM. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combinatino products. Ther Adv Endocrinol Metab. 2018;9(3):69-79.
  32. Novo Nordisk. iDegLira PI. Accessed April 4, 2021.
  33. NYU Langone News. https://nyulangone.org/news/covid-19-brings-telemedicine-fore-diabetes-management. Accessed April 4, 2021. 
  34. Okemah J, Peng J, Quinones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35(11):1735-1745.
  35. Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing fixed-ratio combination therapy in type 2 diabetes. Adv Ther. 2019;36(2):265-277.
  36. Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (iDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189-196.
  37. Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026-2035.
  38. Rosenstock J, Handelsman Y, Vidal J, et al. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018;20(12):2821-2829.
  39. Sanofi-Aventis. iGlarLixi PI. Accessed April 4, 2021.
  40. Skolnik N, Hinnen D, Kiriakov Y, Magwire ML, White JR, Jr. Initiating titratable fixed-ratio combinations of basal insulin analogs and glucagon-like peptide-1 receptor agonists: what you need to know. Clin Diabetes. 2018;36(2):174-182.
  41. Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-1077.